Refine
Is part of the Bibliography
- yes (209)
Year of publication
Document Type
- Journal article (143)
- Doctoral Thesis (63)
- Report (2)
- Review (1)
Keywords
- Neurobiologie (41)
- Glioblastom (11)
- glioblastoma (11)
- Medizin (9)
- Glioblastoma (6)
- Vestibularisschwannom (6)
- Schädel-Hirn-Trauma (5)
- Subarachnoidalblutung (5)
- active zone (5)
- astrocytoma (5)
- glioblastoma multiforme (5)
- glioma (5)
- vestibular schwannoma (5)
- Akustikustumor (4)
- Durchblutung (4)
- Gehirn (4)
- Gliom (4)
- Neurochirurgie (4)
- brain (4)
- rats (4)
- recurrence (4)
- therapy (4)
- Astrozytom (3)
- CXCR4 (3)
- Glioblastoma multiforme (3)
- Hypothalamus (3)
- MGMT (3)
- Prostaglandine (3)
- TRH (3)
- TTFields (3)
- Tumortherapiefelder (3)
- blood pressure (3)
- blood-brain barrier (3)
- brain tumor (3)
- deep brain stimulation (3)
- mRNA (3)
- medulloblastoma (3)
- metabolism (3)
- mice (3)
- neuroprotection (3)
- protein (3)
- rat (3)
- relapse (3)
- subthalamic nucleus (3)
- traumatic brain injury (3)
- ABR (2)
- ADAM9 (2)
- ATF5 (2)
- Akustikusneurinom (2)
- Aneuploidie (2)
- Blut-Hirn-Schranke (2)
- CA3 (2)
- CNS disorders (2)
- COVID-19 (2)
- Delta-Valve (2)
- Elektrocochleographie (2)
- Elektrophysiologie (2)
- Glioma (2)
- Hirntumor (2)
- Hydrocephalus (2)
- Hyperkapnie (2)
- Hypothermie (2)
- Lipopolysaccharide (2)
- MACC1 (2)
- MPS1 (2)
- MRI (2)
- Merlin (2)
- Mesenteric circulation (2)
- Mitose (2)
- NMR-Tomographie (2)
- Neuralgie (2)
- Neurofibromatose (2)
- Neurophysiologie (2)
- Neuroprotektion (2)
- Overdrainage (2)
- Parkinson's disease (2)
- Parkinson’s disease (2)
- RIM1α (2)
- Ratte (2)
- SAH (2)
- Sagittalnahtsynostose (2)
- Schmerz (2)
- Stroke (2)
- TTK (2)
- Tumor Treating Fields (TTFields) (2)
- Tumor-Nekrose-Faktor <alpha> (2)
- Unishunt (2)
- VEGF (2)
- acute brain slices (2)
- animal model (2)
- blood–brain barrier (2)
- brain edema (2)
- cancer stem cells (2)
- cardiac output (2)
- cerebEND (2)
- closed head injury (2)
- contact-kinin system (2)
- depression (2)
- dopamine (2)
- electron tomography (2)
- expression (2)
- factor XII (2)
- fluoroscopy (2)
- heart rate (2)
- high-pressure freezing/freeze substitution (2)
- imaging (2)
- inflammation (2)
- intraoperative imaging (2)
- intraoperative monitoring (2)
- low-grade glioma (2)
- meningioma (2)
- minocycline (2)
- neuropathic pain (2)
- organoids (2)
- pain (2)
- presynaptic (2)
- temozolomide (2)
- tumor necrosis factor (2)
- 2 PM (1)
- 2-photon microscopy (1)
- 3 D rotational fluoroscopy (1)
- 3D cell culture (1)
- 3D ex vivo models (1)
- 3D fluoroscopy (1)
- 3D in vitro model (1)
- 3D-Modell (1)
- ABR Monitoring (1)
- Akustisch evozierte Potentiale (1)
- Akustisch evoziertes Potenzial (1)
- Anaphylactic shock (1)
- Anaphylaxis (1)
- Aneurysma (1)
- Apoptosis (1)
- Astrocytic tumor (1)
- Astrocytoma (1)
- Astrozytäre Tumore (1)
- Audiologie (1)
- Auditory brainstem implant (1)
- Augenhintergrund (1)
- Autoradiography (1)
- Axonal degeneration (1)
- BDNF (1)
- BN 52021 (1)
- BRMS1 (1)
- Bauchaorta (1)
- Bevacizumab (1)
- Biomarker (1)
- Biowissenschaften (1)
- Blood–brain barrier (1)
- Blutdruck (1)
- Bone chips (1)
- Bradykininantagonist (1)
- Brain stem (1)
- Bruchpilot (1)
- C1-Inhibitor Berinert (1)
- C1-inhibitor (1)
- C6 (1)
- C6 cells (1)
- C6-Zellen (1)
- CA-IX (1)
- CA2+ channels (1)
- CA3 pyrimidal cells (1)
- CAD-CAM (1)
- CBF (1)
- CD133 (1)
- CNS cancer (1)
- CNS diseases (1)
- CRPS (1)
- CSVD (1)
- CX3CL1 (1)
- CXCL12 (1)
- CXCL13 (1)
- Cardiovascular (1)
- Cardiovascular system (1)
- Cefotaxim (1)
- Cell cycle regulation (1)
- Cerebral Ischemia (1)
- Cerebral-ischemia (1)
- Cranial window (1)
- Crespi effect (1)
- Cytokine (1)
- Dekompressionsoperation (1)
- Delayed cerebral infarction (1)
- Delayed ischemic neurological deficit (1)
- Demenz (1)
- Detektion (1)
- Diabetische Polyneuropathie (1)
- Doxycyclin (1)
- Drosophila melanogaster (1)
- ECoG (1)
- ED2 (1)
- EEG (1)
- EPO (1)
- EVAR (1)
- Early Brain Injury (1)
- Electric auditory brainstem response (1)
- Endothelial cell (1)
- Endothelium (1)
- Endothelzelle (1)
- Endurant® (1)
- Erythropoetin (1)
- Experimentaltumor (1)
- Expression (1)
- Exzitatorische Synapse (1)
- FAEP (1)
- FTY720 (1)
- Facialisl�hmung (1)
- Facialisparese (1)
- Feinmotorik (1)
- Fibrin glue (1)
- Fluorescence (1)
- Focal brain ischemia (1)
- Frühphase nach experimenteller Subarachnoidalblutung (1)
- Genetik (1)
- Genexpression (1)
- Glioblastoma cell line (1)
- Glioblastomas (1)
- Glioma stem cells (1)
- Granulozyten-Makrophagen-koloniestimulierender Faktor Leukomax (rekombinant hergestelltes Präparat) (1)
- Graphiktablett (1)
- HBMVEC (1)
- HBMVEC Zellkultur (1)
- HBO (1)
- HERV-K (1)
- HIF-1 (1)
- Head-injury (1)
- Hemodynamic depression (1)
- Hemorrhage (1)
- Hippocampus (1)
- Hirnblutung (1)
- Hirndruck (1)
- Hirnödem (1)
- Histologie (1)
- Human endogenous retrovirus (1)
- Hydroxyethylstärke (1)
- Hyper-HES (1)
- Hypertension (1)
- Hypophyse (1)
- Hypophysenhormon (1)
- Hypoxia (1)
- Hypoxie (1)
- Hörprothese (1)
- Hörrehabilitation (1)
- IBA-1 (1)
- IDH (1)
- IDH1/2 (1)
- IL-6 (1)
- IOM (1)
- ISBI (1)
- Icosanoid (1)
- Immunhistochemie (1)
- Immunostimulatory adjuvant (1)
- Immunotherapy (1)
- Impressiones digitatae (1)
- In vitro models (1)
- In vivo imaging (1)
- In-vivo dia lysis (1)
- Indikationsstellung (1)
- Infiltration (1)
- IntelliCage (1)
- Intercellular adhesion molecule 1 (1)
- Interleukin 1 beta Neutralisierung (1)
- Interleukin 1-beta (1)
- Intraoperatives Monitoring (1)
- Intravascular coagulation (1)
- Intravital imaging (1)
- Invasion (1)
- Irradiation (1)
- KIF (1)
- KIF11 (1)
- Kephalometrie (1)
- KiSS1 (1)
- Kleinhirn-Brückenwinkeltumor (1)
- Kleinhirnbrückenwinkel (1)
- Kleinhirnbrückenwinkeltumor (1)
- Knochentumor (1)
- Kognition (1)
- Komplikation (1)
- Komplikationen (1)
- Kontakt-Kinin-System (1)
- Kraniopharyngeom (1)
- Kranioplastik (1)
- Kraniosynostose (1)
- Körperachse (1)
- LGA (1)
- LTD (1)
- Langzeitdepression (1)
- Lateral suboccipital craniectomy (1)
- Lebensqualität (1)
- Lipoxin (1)
- Literatur (1)
- Locus coeruleus (1)
- Low grade Astrocytoma (1)
- MEA (1)
- MGMT promoter methylation (1)
- MMP (1)
- MMP9 (1)
- MRT (1)
- Mad2A und Mad2B (1)
- Makrophagen (1)
- Mapping <Medizin> (1)
- Marklager (1)
- Matrix-Metalloprotease (1)
- Matrixmetalloproteinasen (1)
- Medulloblastom (1)
- Medulloblastome (1)
- Meningeom (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- Methylierung (1)
- Methylprednisolon (1)
- Mice (1)
- Microbubbles (1)
- Microinjection (1)
- Mikrochirurgie (1)
- Minozyklin (1)
- Model (1)
- Molecular-weight heparin (1)
- Monocyte (1)
- Monopolar spindle 1 (1)
- Morbus Fabry (1)
- Motorischer Cortex (1)
- Mouse model (1)
- Multielectrode Array (1)
- Multielektroden Arrays (1)
- Myelographie (1)
- Myelopathie (1)
- N-Acetyl-leukotriene E4 (1)
- NADPH oxidases (NOX) (1)
- NCH93 (1)
- NDRG1 (1)
- NF-2 (1)
- NT-3 (1)
- Neoangiogenese (1)
- Nervus facialis (1)
- Nervus vestibulocochlearis (1)
- Nestin (1)
- Neugeborenes (1)
- Neurodegeneration (1)
- Neurofibromatose Typ 2 (1)
- Neuroinflammation (1)
- Neurologie (1)
- Neuromonitoring (1)
- Neuronale Netzwerke (1)
- Neuronale Plastizität (1)
- Neuronavigation (1)
- Neuronclusters (1)
- Neurons (1)
- Neuropeptides (1)
- Neuroprotection (1)
- Neurotrophe Faktoren (1)
- Neurowissenschaften (1)
- Notfall (1)
- O(6)-Methylguanine-DNA Methyltransferase (1)
- O-Arm (1)
- Oncolysis (1)
- Onkologie (1)
- Osteogeneration (1)
- Osteopontin (1)
- Outcome (1)
- PAF-acether (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PDH (1)
- PET (1)
- PET/CT (1)
- PFA in ethanol (1)
- PMMA (1)
- Paclitaxel (1)
- Pds5A und Pds5B (1)
- Pedikelschraube (1)
- Pentixafor (1)
- Peptide-leukotrienes (1)
- Phase II trials (1)
- Physiologie (1)
- Polymethylmethacrylate (1)
- Polyneuropathie (1)
- Proliferation (1)
- Prostaglandins (1)
- Proteasomenaktivator (1)
- Pyruvatdehydrogenase-Komplex (1)
- R-715 (1)
- RECK (1)
- RIM-binding protein (1)
- RPS27 (1)
- RS-13 (1)
- Rat hippocampus (1)
- Rats (1)
- Real time quantitative PCR (1)
- Regression (1)
- Rehabilitation (1)
- Renal circulation (1)
- Reperfusion (1)
- Resektion (1)
- Revision (1)
- Rezeptor Tyrosin Kinase (1)
- SARS-CoV-2 (1)
- SHRSP (1)
- SOAT1 (1)
- SSEP (1)
- SV pool (1)
- Schmerzforschung (1)
- Schrauben-Stab-Osteosynthese (1)
- Schraubenlage (1)
- Schädelchirurgie (1)
- Schädelnaht (1)
- Silver degeneration staining (1)
- Slice Culture (1)
- Spinal dissemination (1)
- Spinalkanalstenose (1)
- Spindle assembly checkpoint (1)
- Staphylococcus (1)
- Star-PEG (1)
- Stauungspapille (1)
- Stentgraft (1)
- Störungen der Feinmotorik (1)
- Subarachnoid hemorrhage (1)
- Subarachnoidalblutung Neuroprotektion Frühphase Nitroprussid Notfall (1)
- Supraoptic nucleus (1)
- Surgery (1)
- Sympathetic nervous system (1)
- Synaptische Transmission (1)
- Synaptische Vesikel (1)
- T-2 toxin (1)
- TBI (1)
- TNF (1)
- TNF-α (1)
- TSPO (1)
- Taxol (1)
- Temozolomide (1)
- Therapie (1)
- Thromboplastin (1)
- Thrombus formation (1)
- Thyreotropin-Releasinghormon (1)
- Tiermodell (1)
- Tierversuch (1)
- Trauma (1)
- Traumatic brain injury (1)
- Trepanation (1)
- Tumor (1)
- Tumor Treating Fields (1)
- Tumor-Nekrose-Faktor (1)
- Tumor-Nekrose-Faktor <alpha>-Inhibitor (1)
- Tumor-Treating Fields (TTFields) (1)
- Tumorentstehung (1)
- Tumorinvasion (1)
- Tumorwachstum (1)
- Ultraschall (1)
- Uniparentale Stammzellen (1)
- VLSM (1)
- Vaskularisation (1)
- Vasopressin (1)
- Ventilation (1)
- Vincristin (1)
- Voluven (1)
- Von Willebrand factor (1)
- WNT signaling (1)
- Willebrand-Faktor (1)
- Wirbelkanalstenose (1)
- Wirbelsäule (1)
- Wolkenschädel (1)
- Zdichavsky (1)
- Zell-Adhäsionsmolekül (1)
- Zellkultur (1)
- Zellzyklusregulation (1)
- Zervikale Myelopathie (1)
- [3H][3Me-His2]-TRH (1)
- \(^{68}\)Ga-Pentixafor (1)
- accelerator based radiosurgery (1)
- acoustic (1)
- acoustic neuroma (1)
- acoustic startle (1)
- adherence (1)
- adolescence (1)
- aerobic glycolysis (1)
- aesthetic results (1)
- aging (1)
- alkaline phosphatase (1)
- amplitude criterion (1)
- amyloidoma (1)
- anaplastic medulloblastoma (1)
- aneurysm (1)
- aneurysmatisch (1)
- anticancer activity (1)
- anxiety (1)
- asfotase alfa (1)
- assoziative Paarstimulation (1)
- astocytoma (1)
- astrocytes (1)
- astrocytic tumor (1)
- astroglia (1)
- atrial fibrillation (1)
- audiometry (1)
- auditory brainstem responses (1)
- autoradiography (1)
- beaten copper markings (1)
- behavior (1)
- benzodiazepine antagonist. (1)
- beta oscillations (1)
- blastocysts (1)
- blood brain barier (1)
- blood brain barrier (1)
- blood nerve barrier (1)
- blood-brain-barrier (1)
- body axis (1)
- bone (1)
- bradykinin (1)
- bradykinin antagonist (1)
- brain development (1)
- brain-injury (1)
- brainstem auditory evoked potentials (1)
- braintumor (1)
- c6 (1)
- cancer (1)
- catecholamlnes (1)
- cefotaxime (1)
- cerebEND Zellkultur (1)
- cerebEND cells (1)
- cerebraI ischemia (1)
- cerebraler Blutfluss (1)
- cerebrovascular disorders (1)
- cerebrovascular surgery (1)
- cerebrovaskuläre Chirurgie (1)
- cervical spine (1)
- chemokine receptor-4 (1)
- chemotherapy (1)
- childhood (1)
- children (1)
- chlorisondamine (1)
- chronic heart failure (1)
- chronic stimulation (1)
- cip (1)
- claudin-1 (1)
- clinical trials (1)
- cognitive function (1)
- cognitive functions (1)
- cognitive impairment (1)
- coherence analysis (1)
- communicating networks (1)
- compaction (1)
- complications (1)
- craniofacial orthodontics (1)
- craniopharyngioma (1)
- cranioplasty (1)
- craniovertebral junction (1)
- critical-illness-polyneuropathie (1)
- ct-scan (1)
- cytokine (1)
- cytokines (1)
- dSTORM (1)
- damage control orthopedics (1)
- deformational cranial asymmetry (1)
- dementia (1)
- dennorphin (1)
- derivation (1)
- dermorphin (1)
- dexamethasone (1)
- differentiation (1)
- diffuse (1)
- diffuse astrocytoma (1)
- digitales Graphiktablett (1)
- direct cortical stimulation (1)
- directional deep brain stimulation (1)
- distress (1)
- double-blind (1)
- doxycycline (1)
- early brain injury (1)
- early detection (1)
- edema (1)
- electrocochleography (1)
- erythropoietin (1)
- etanercept (1)
- executive function (1)
- experimental stroke (1)
- expression pattern (1)
- facial nerv (1)
- femoral fracture (1)
- flumazenil (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral-ischemia (1)
- frameless systems (1)
- frühe ischämische Ereignisse (1)
- frührehabilitation (1)
- gamma knife radiosurgery (1)
- glia (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- gliom (1)
- glucocorticoid receptor (1)
- group 3 (1)
- guidelines (1)
- head (1)
- hearing preservation (1)
- hemorrhagic shock (1)
- high-pressure freezing (1)
- hippocampal (1)
- hippocampal mossy fiber bouton (1)
- histological findings (1)
- homeostasis (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cells (1)
- hypophosphatasia (1)
- hypothermia (1)
- hypovolemic hypotension (1)
- hypoxia (1)
- image-guided programming (1)
- immunofluorescence (1)
- immunofuorescence double staining (1)
- immunohistochemistry (1)
- in vitro (1)
- in vitro model (1)
- in vivo (1)
- in-vitro (1)
- in-vivo (1)
- induced stem cells (1)
- induzierte Stammzellen (1)
- infants with deformational plagiocephaly (DP) (1)
- infiltration (1)
- inflammatory mechanisms (1)
- integrin (1)
- internalized stigmatization (1)
- intracranial pressure (1)
- intraoperatives Monitoring (1)
- invasion (1)
- ischemia (1)
- ischemic events (1)
- isoliert (1)
- isosteviol sodium (1)
- isosteviol sodium (STVNA) (1)
- kallikrein–kinin system (1)
- kinematische Parameter (1)
- kinesin (1)
- kinin receptor (1)
- kinin receptors (1)
- knock down (1)
- kognitive Beeinträchtigung (1)
- lesion symptom mapping (1)
- lines (1)
- lipid droplets (1)
- liponeurocytoma (1)
- lipopolysaccharides (1)
- liquid biopsy (1)
- literature (1)
- lnflammation (1)
- local field potentials (1)
- locus coeruleus (1)
- long-term depression (1)
- lower grade glioma (1)
- mRNA expression (1)
- macrophages (1)
- management (1)
- mapping (1)
- matrix metalloproteinase (1)
- matrix-metalloproteinase (1)
- mechanism of action (1)
- memory (1)
- metastasis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- methylprednisolone (1)
- microRNA (1)
- microglia (1)
- microsurgery (1)
- mikrochirurgische Resektion (1)
- minimally invasive (1)
- mitotane (1)
- modulation (1)
- molecular imaging (1)
- molecular signature (1)
- mononuclear phagocytes (1)
- mortality (1)
- mossy fiber synapse (1)
- mossy fiber synapses (1)
- motor control (1)
- motor cortex (1)
- mouse-brain (1)
- movement (1)
- movement disorders (1)
- mri (1)
- multifocal growth (1)
- multiple sclerosis (1)
- mycotoxin (1)
- myocardial infarction (1)
- naloxonazine (1)
- naloxone (1)
- nanotopology (1)
- nausea and emesis (1)
- neoangiogenesis (1)
- neonatal (1)
- nervous-sytem (1)
- neuonal differentiation (1)
- neural stem-cells (1)
- neurobehavioral deficits (1)
- neurocytoma (1)
- neurodegenerative disease (1)
- neurofibromatosis (1)
- neurofibromatosis type 2 (1)
- neuroinflammation (1)
- neurological complications (1)
- neurology (1)
- neuroma (1)
- neuromuscular junction (1)
- neuronal damage (1)
- neuronal plasticity (1)
- neuronale Differenzierung (1)
- neuronavigation (1)
- neurooncology (1)
- neuropathy (1)
- neuropsychologische Testbatterie (1)
- neurosurgery (1)
- neurotrophic factor (1)
- neurovascular disorders (1)
- neurovascular unit (1)
- non-VKA oral anticoagulants (1)
- non-small cell lung cancer (NSCLC) (1)
- nucleus (1)
- object recognition memory (1)
- obsessive-compulsive disorder (1)
- occupation (1)
- oligodendroglioma (1)
- opiates (1)
- opioid peptides (1)
- opioid receptors (1)
- opioid-benzodiazepine interactions (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- outcome (1)
- ovarian cancer (1)
- oxidative stress (1)
- paclitaxel (1)
- paediatric cancer (1)
- painful neuropathy (1)
- paired associative stimulation (1)
- palladium (1)
- pancreatic cancer (1)
- papilledema (1)
- paragangliomas (1)
- pathogenesis (1)
- pedicle screws (1)
- physical examination (1)
- plasticity (1)
- platelet activating factor (1)
- platelet-activating factor (1)
- platform (1)
- platinum (1)
- pluripotent (1)
- positionalskull deformities (1)
- positron emission tomography/computed tomography (1)
- postoperative Phase (1)
- presynaptic plasticity (1)
- prevention (1)
- primary cell culture (1)
- progenitors (1)
- prognostic marker (1)
- proliferation (1)
- prostacyclins (1)
- proteins (1)
- pränatal (1)
- psychiatric disorders (1)
- pterionaler Zugang (1)
- pyramidal neurons (1)
- quality of life (1)
- radiation therapy (1)
- radiotherapy (1)
- randomized controlled double-blind study (1)
- rare bone disease (1)
- ratten (1)
- real time PCR (1)
- receptor tyrosine kinase (1)
- recombinat-human-erythropoietin (1)
- reflex (1)
- regional blood flow (1)
- regional blood ftow (1)
- regression (1)
- rehabilitation (1)
- release (1)
- renin (1)
- resilience (1)
- resistance (1)
- respiration (1)
- reveals (1)
- rickets (1)
- sagittal synostosis (1)
- scale (1)
- scaphocephaly (1)
- schizophrenia (1)
- secondary brain damage (1)
- senescence (1)
- serotonin (1)
- shock (1)
- skull base (1)
- slice culture (1)
- specification (1)
- spinal tumor operation (1)
- spine (1)
- spontane (1)
- spontaneous regression (1)
- stereotaxy (1)
- stress (1)
- stress signaling (1)
- stroke (1)
- stroke therapy (1)
- subarachnoid hemorrhage (1)
- subarachnoid hemorrhage (SAH) (1)
- subjective perception (1)
- super-resolution microscopy (1)
- suppressor (1)
- surgery (1)
- sympathetic nerve activity. (1)
- synaptic ultrastructure (1)
- tPA (1)
- targeted therapy (1)
- taxanes (1)
- temporal bone (1)
- therapy response (1)
- thiosemicarbazone (1)
- three-dimensional (1)
- three-dimensional imaging (1)
- threshold criterion (1)
- threshold level (1)
- thromboinflammation (1)
- thrombosis (1)
- thymectomized rats (1)
- tnf (1)
- total peripheral resistance (1)
- transcranial motor-evoked potentials (1)
- transient ischemic attack (1)
- tumor (1)
- tumor development (1)
- tumor slice cultures (1)
- tumor treating fields (1)
- tumor-invasion (1)
- tumor-necrosis-factor (1)
- tumormicroenvironment (1)
- uPA (1)
- vascularisation (1)
- vasopressin (1)
- vertebral pedicles (1)
- vincristine (1)
- vitamin K antagonists (1)
- von Willebrand factor (1)
- warfarin (1)
- weight drop (1)
- µ opioid receptors (1)
- µ·Opioid receptor subtypes (1)
- ästhetische Ergebnisse (1)
- β-APP (1)
Institute
- Neurochirurgische Klinik und Poliklinik (209) (remove)
Sonstige beteiligte Institutionen
Current data show that resilience is an important factor in cancer patients’ well-being. We aim to explore the resilience of patients with lower grade glioma (LGG) and the potentially influencing factors. We performed a cross-sectional assessment of adult patients with LGG who were enrolled in the LoG-Glio registry. By phone interview, we administered the following measures: Resilience Scale (RS-13), distress thermometer, Montreal Cognitive Assessment Test for visually impaired patients (MoCA-Blind), internalized stigmatization by brain tumor (ISBI), Eastern Cooperative Oncological Group performance status (ECOG), patients’ perspective questionnaire (PPQ) and typical clinical parameters. We calculated correlations and multivariate regression models. Of 74 patients who were assessed, 38% of those showed a low level of resilience. Our results revealed significant correlations of resilience with distress (p < 0.001, −0.49), MOCA (p = 0.003, 0.342), ECOG (p < 0.001, −0.602), stigmatization (p < 0.001, −0.558), pain (p < 0.001, −0.524), and occupation (p = 0.007, 0.329). In multivariate analyses, resilience was negatively associated with elevated ECOG (p = 0.020, β = −0.383) and stigmatization levels (p = 0.008, β = −0.350). Occupation showed a tendency towards a significant association with resilience (p = 0.088, β = −0.254). Overall, low resilience affected more than one third of our cohort. Low functional status is a specific risk factor for low resilience. The relevant influence of stigmatization on resilience is a novel finding for patients suffering from a glioma and should be routinely identified and targeted in clinical routine.
Einführung
Die Kranioplastik (KP) nach Kraniektomie dient der Wiederherstellung der Funktionalität und Ästhetik des Schädels. Obwohl es sich um einen Routineeingriff handelt, wurden hohe Komplikationsraten beschrieben, die zum Teil auf die unterschiedlichen Arten des verwendeten Implantatmaterials zurückzuführen sind. Wir haben diese Studie durchgeführt, um intraoperativ-geformte (Palacos®) und CAD-CAM-PMMA-Implantate bei Patienten/-innen nach Kraniektomie hinsichtlich perioperativer Modalitäten, kurz- und langfristiger Komplikationsraten und ästhetischer Ergebnisse zu vergleichen.
Methoden
Diese retrospektive Single-Center-Analyse wurde an 350 Patienten mit 359 Kranioplastiken durchgeführt, die sich in 133 Palacos®-Fälle (01/2005-12/2012) und 226 CAD-CAM-Fälle (01/2010-12/2018) aufteilten. Postoperative Komplikationen wurden in kurzfristige (≤ 30 Tage) und langfristige (> 30 Tage) unterteilt. Die ästhetischen Ergebnisse wurden per Telefoninterview erhoben und auf einer 5-Punkte-Skala bewertet.
Ergebnisse
CAD-CAM-Patienten hatten eine kürzere Operationszeit (p < 0.001), einen geringeren intraoperativen Blutverlust (p < 0.001) und einen kürzeren postoperativen Krankenhausaufenthalt (p < 0.005) als Palacos®-Patienten. Operative Revisionen nach CP mussten bei 12,8 % der Patienten durchgeführt werden. Implantatinfektionen traten bei 3,8 % der Palacos®-Fälle und 1,8 % der CAD-CAM-Fälle auf. Wundheilungsstörungen traten bei CAD-CAM-Patienten häufiger auf, was mit einer höheren Anzahl an kraniellen Vor-Operationen und Vorinfektionen einherging. Palacos®-Patienten hatten signifikant mehr Implantatdislokationen (p < 0.05). CAD-CAM-Patienten berichteten von einem besseren ästhetischen Ergebnis im Vergleich zu Palacos®-Patienten.
Fazit
Diese Studie zeigt eine Überlegenheit der CAD-CAM-PMMA-Implantate im Vergleich zu Palacos®-Implantaten hinsichtlich peri- und postoperativer Faktoren, sowie dem ästhetischen Ergebnis. CAD-CAM-Implantate haben geringere Komplikations- und Infektionsraten als Palacos®-Implantate und zeigten positive Wirkungen, wenn sie in vorinfiziertes Gewebe implantiert wurden. Die langfristigen Komplikationsraten von CAD-CAM-Implantaten müssen weiter evaluiert werden.
Early treatment with glucocorticoids could help reduce both cytotoxic and vasogenic edema, leading to improved clinical outcome after stroke. In our previous study, isosteviol sodium (STVNA) demonstrated neuroprotective effects in an in vitro stroke model, which utilizes oxygen-glucose deprivation (OGD). Herein, we tested the hypothesis that STVNA can activate glucocorticoid receptor (GR) transcriptional activity in brain microvascular endothelial cells (BMECs) as previously published for T cells. STVNA exhibited no effects on transcriptional activation of the glucocorticoid receptor, contrary to previous reports in Jurkat cells. However, similar to dexamethasone, STVNA inhibited inflammatory marker IL-6 as well as granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion. Based on these results, STVNA proves to be beneficial as a possible prevention and treatment modality for brain ischemia-reperfusion injury-induced blood–brain barrier (BBB) dysfunction.
Despite the availability of numerous therapeutic substances that could potentially target CNS disorders, an inability of these agents to cross the restrictive blood–brain barrier (BBB) limits their clinical utility. Novel strategies to overcome the BBB are therefore needed to improve drug delivery. We report, for the first time, how Tumor Treating Fields (TTFields), approved for glioblastoma (GBM), affect the BBB’s integrity and permeability. Here, we treated murine microvascular cerebellar endothelial cells (cerebEND) with 100–300 kHz TTFields for up to 72 h and analyzed the expression of barrier proteins by immunofluorescence staining and Western blot. In vivo, compounds normally unable to cross the BBB were traced in healthy rat brain following TTFields administration at 100 kHz. The effects were analyzed via MRI and immunohistochemical staining of tight-junction proteins. Furthermore, GBM tumor-bearing rats were treated with paclitaxel (PTX), a chemotherapeutic normally restricted by the BBB combined with TTFields at 100 kHz. The tumor volume was reduced with TTFields plus PTX, relative to either treatment alone. In vitro, we demonstrate that TTFields transiently disrupted BBB function at 100 kHz through a Rho kinase-mediated tight junction claudin-5 phosphorylation pathway. Altogether, if translated into clinical use, TTFields could represent a novel CNS drug delivery strategy.
Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O\(^6\)-methylguanine-DNA methyltransferase (MGMT). The MGMT promoter methylation, the main regulator of MGMT expression, can change from primary tumor to recurrence, and TMZ may play a significant role in this process. To identify the potential mechanisms involved, three primary stem-like cell lines (one astrocytoma with the mutation of the isocitrate dehydrogenase (IDH), CNS WHO grade 4 (HGA)), and two glioblastoma (IDH-wildtype, CNS WHO grade 4) were treated with TMZ. The MGMT promoter methylation, migration, proliferation, and TMZ-response of the tumor cells were examined at different time points. The strong effects of TMZ treatment on the MGMT methylated cells were observed. Furthermore, TMZ led to a loss of the MGMT promoter hypermethylation and induced migratory rather than proliferative behavior. Cells with the unmethylated MGMT promoter showed more aggressive behavior after treatment, while HGA cells reacted heterogenously. Our study provides further evidence to consider the potential adverse effects of TMZ chemotherapy and a rationale for investigating potential relationships between TMZ treatment and change in the MGMT promoter methylation during relapse.
Ten thiosemicarbazone ligands obtained by condensation of pyridine-2-carbaldehyde, quinoline-2-carbaldehyde, 2-acetylpyridine, 2-acetylquinoline, or corresponding 2-pyridyl ketones with thiosemicarbazides RNHC(S)NHNH\(_{2}\) and R=CH\(_{3}\), C\(_{6}\)H\(_{5}\) were prepared in good yield. The reaction of [PdCl\(_{2}\)(cod)] with cod=1,5-cyclooctadiene or K\(_{2}\)[PtCl\(_{4}\)] resulted in a total of 17 Pd(II) and Pt(II) complexes isolated in excellent purity, as demonstrated by \(^{1}\)H, \(^{13}\)C, and, where applicable, \(^{195\)Pt NMR spectroscopy combined with CHNS analysis. The cytotoxicity of the title compounds was studied on four human glioblastoma cell lines (GaMG, U87, U138, and U343). The most active compound, with a Pd(II) metal centre, a 2-quinolinyl ring, and methyl groups on both the proximal C and distal N atoms exhibited an EC\(_{50}\) value of 2.1 μM on the GaMG cell lines, thus being slightly more active than cisplatin (EC\(_{50}\) 3.4 μM) and significantly more potent than temozolomide (EC\(_{50}\) 67.1 μM). Surprisingly, the EC\(_{50}\) values were inversely correlated with the lipophilicity, as determined with the “shake-flask method”, and decreased with the length of the alkyl substituents (C\(_{1}\)>C\(_{8}\)>C\(_{10}\)). Correlation with the different structural motifs showed that for the most promising anticancer activity, a maximum of two aromatic rings (either quinolinyl or pyridyl plus phenyl) combined with one methyl group are favoured and the Pd(II) complexes are slightly more potent than their Pt(II) analogues.
Both nerve injury and complex regional pain syndrome (CRPS) can result in chronic pain. In traumatic neuropathy, the blood nerve barrier (BNB) shielding the nerve is impaired—partly due to dysregulated microRNAs (miRNAs). Upregulation of microRNA-21-5p (miR-21) has previously been documented in neuropathic pain, predominantly due to its proinflammatory features. However, little is known about other functions. Here, we characterized miR-21 in neuropathic pain and its impact on the BNB in a human-murine back translational approach. MiR-21 expression was elevated in plasma of patients with CRPS as well as in nerves of mice after transient and persistent nerve injury. Mice presented with BNB leakage, as well as loss of claudin-1 in both injured and spared nerves. Moreover, the putative miR-21 target RECK was decreased and downstream Mmp9 upregulated, as was Tgfb. In vitro experiments in human epithelial cells confirmed a downregulation of CLDN1 by miR-21 mimics via inhibition of the RECK/MMP9 pathway but not TGFB. Perineurial miR-21 mimic application in mice elicited mechanical hypersensitivity, while local inhibition of miR-21 after nerve injury reversed it. In summary, the data support a novel role for miR-21, independent of prior inflammation, in elicitation of pain and impairment of the BNB via RECK/MMP9.
Based on recent findings that show that depletion of factor XII (FXII) leads to better posttraumatic neurological recovery, we studied the effect of FXII-deficiency on post-traumatic cognitive and behavioral outcomes in female and male mice. In agreement with our previous findings, neurological deficits on day 7 after weight-drop traumatic brain injury (TBI) were significantly reduced in FXII\(^{−/−}\) mice compared to wild type (WT) mice. Also, glycoprotein Ib (GPIb)-positive platelet aggregates were more frequent in brain microvasculature of WT than FXII\(^{−/−}\) mice 3 months after TBI. Six weeks after TBI, memory for novel object was significantly reduced in both female and male WT but not in FXII\(^{−/−}\) mice compared to sham-operated mice. In the setting of automated home-cage monitoring of socially housed mice in IntelliCages, female WT mice but not FXII\(^{−/−}\) mice showed decreased exploration and reacted negatively to reward extinction one month after TBI. Since neuroendocrine stress after TBI might contribute to trauma-induced cognitive dysfunction and negative emotional contrast reactions, we measured peripheral corticosterone levels and the ration of heart, lung, and spleen weight to bodyweight. Three months after TBI, plasma corticosterone levels were significantly suppressed in both female and male WT but not in FXII\(^{−/−}\) mice, while the relative heart weight increased in males but not in females of both phenotypes when compared to sham-operated mice. Our results indicate that FXII deficiency is associated with efficient post-traumatic behavioral and neuroendocrine recovery.
Glioblastoma (GBM) sind bösartige hirneigene Tumore, deren schlechte Prognose einer innovativen Therapie bedarf. Aus diesem Grund wurde ein neuer Therapieansatz entwickelt, der auf einer lokalen Ultraschall-vermittelten Zytostatika Applikation beruht. Hierfür wurden stabile Microbubbles (MB) bestehend aus Phospholipiden synthetisiert. Es konnte gezeigt werden, dass MB als auch fokussierter Ultraschall niedriger Intensität (LIFU) keinen negativen Einfluss auf GBM-Zellen hat. MB hingegen konnten mittels LIFU destruiert werden, wodurch das in den MB eingeschlossene Chemotherapeutikum freigesetzt werden kann. Es wurden verschiedene Platin(II)- und Palladium(II)-Komplexe auf GBM Zellen getestet. Zur Beladung der MB wurde Doxorubicin (Dox) verwendet. Es konnte eine Beladungseffizienz der MB mit Dox von 52 % erreicht werden, auch eine Aufreinigung dieser mittel Ionenaustausch-Chromatographie und Dialyse war erfolgreich. Die Austestung der mit Dox beladenen MB (MBDox) erfolgte auf GBM-Zellen in 2D- und 3D-Zelkulturmodellen. Dabei zeigte sich, dass die Behandlung mit MBDox und LIFU für 48 h eine zytotoxische Wirkung hatte, die sich signifikant von der Behandlung mit MBDox ohne LIFU unterschied. Zur Austestung der MBDox in 3D-Zellkulturmodellen wurden zwei Scaffold-Systeme eingesetzt. Es zeigte sich in den Versuchen, dass MBDox mit LIFU im Vergleich zu MBDox ohne LIFU Applikation einen zytotoxischen Effekt auf GBM-Zellen haben. Somit konnte die Wirksamkeit der Zytostatika Applikation mittels MB und LIFU in 2D- und 3D-Zellkulturmodellen erfolgreich etabliert werden. Als weiterer Schritt wurden zwei 3D in vitro Modelle erarbeitet. Dabei wurden zunächst organotypische hippocampale Slice Kulturen (organotypic hippocampal brain slice cultures, OHSC) aus der Maus hergestellt und anschließend mit fluoreszent-markierten Mikrotumoren aus GBM-Zelllinien, Primärzellen (PZ) und aus Patienten generierten GBM-Organoiden hergestellt. Diese GBM-Modelle wurden mit Tumor Treating Fields (TTFields) behandelt. Dabei war eine Abnahme der Tumorgröße von Mikrotumoren aus GBM-Zellen und PZ unter TTFields-Behandlung für 72 h messbar. Als weiteres in vitro Modell wurden humane Tumorschnitte aus intraoperativ entferntem GBM-Patientenmaterial hergestellt. Die Schnitte wiesen ein heterogenes Ansprechen nach 72 h TTFields-Applikation auf. Dies spiegelt die Heterogenität des GBM sehr gut wider und bestärkt die Eignung des Modelles zur Untersuchung von neuen Therapieansätzen zur Behandlung von GBM.
MACC1 - ein prognostischer Blutmarker für das Überleben von Patienten mit Glioblastoma multiforme?
(2023)
Das GBM ist der aggressivste primäre Hirntumor bei Erwachsenen ohne bekannten Tumormarker. Wir haben im Blutplasma zirkulierende mRNA Transkripte von MACC1, einem prognostischen Biomarker für solide Tumoren, auf ihre Korrelation mit dem klinischem Outcome und der Therapieantwort bei GBM-Patienten getestet. MACC1 mRNA Transkripte waren signifikant erhöht bei GBM-Patienten im Vergleich zur Kontrollgruppe. Eine niedrige MACC1 mRNA Transkript-Konzentration clusterte mit anderen prognostisch wertvollen Faktoren, wie z.B. dem IDH1 Mutationsstatus: Patienten mit der IDH1 R132H Mutation in Kombination mit einer niedrigen MACC1 mRNA Transkript-Konzentration wiesen das längste Gesamtüberleben von über 2 Jahren auf, IDH1 wildtyp und eine hohe MACC1 mRNA Transkript-Konzentration führten zum schlechtesten Outcome (medianes Gesamtüberleben 8,1 Monate). Patienten mit IDH1 wildtyp und einer niedriger MACC1 mRNA Transkript-Konzentration waren intermediär (medianes Gesamtüberleben 9,1 Monate). Kein Patient hatte eine IDH1 R132H Mutation und eine hohe MACC1 mRNA Transkript-Konzentration. Patienten mit niedriger MACC1 mRNA Transkript-Konzentration, die die Standardtherapie nach Stupp erhielten, überlebten länger (medianes Gesamtüberleben 22,6 Monate) als Patienten mit einer hohen MACC1 mRNA Transkript-Konzentration (medianes Gesamtüberleben 8,1 Monate). Patienten, die keine Standardtherapie erhielten, zeigten das schlechteste Outcome, unabhängig von der MACC1 mRNA Transkript-Konzentration (niedrig: 6,8 Monate, hoch: 4,4 Monate). Durch das Hinzufügen der MACC1 mRNA TranskriptKonzentrationen zur präoperativen Diagnostik könnte somit die Prognose und das Outcome von GBM Patienten genauer evaluiert werden und so eine genauere Einteilung in Therapie- und Risikogruppen erfolgen